- Home
- KULR vs CADL Comparison
KULR vs CADL Comparison
Compare KULR & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KULR
- CADL
- Stock Information
- Founded
- KULR 2013
- CADL 1999
- Country
- KULR United States
- CADL United States
- Employees
- KULR N/A
- CADL N/A
- Industry
- KULR Electrical Products
- CADL Biotechnology: Pharmaceutical Preparations
- Sector
- KULR Technology
- CADL Health Care
- Exchange
- KULR Nasdaq
- CADL Nasdaq
- Market Cap
- KULR 275.2M
- CADL 306.4M
- IPO Year
- KULR N/A
- CADL 2021
- Fundamental
- Price
- KULR $1.22
- CADL $4.57
- Analyst Decision
- KULR Strong Buy
- CADL Strong Buy
- Analyst Count
- KULR 2
- CADL 4
- Target Price
- KULR $5.00
- CADL $21.00
- AVG Volume (30 Days)
- KULR 11.6M
- CADL 1.1M
- Earning Date
- KULR 05-14-2025
- CADL 05-13-2025
- Dividend Yield
- KULR N/A
- CADL N/A
- EPS Growth
- KULR N/A
- CADL N/A
- EPS
- KULR N/A
- CADL N/A
- Revenue
- KULR $10,737,481.00
- CADL N/A
- Revenue This Year
- KULR $72.05
- CADL N/A
- Revenue Next Year
- KULR $180.69
- CADL N/A
- P/E Ratio
- KULR N/A
- CADL N/A
- Revenue Growth
- KULR 9.23
- CADL N/A
- 52 Week Low
- KULR $0.20
- CADL $3.79
- 52 Week High
- KULR $5.49
- CADL $14.60
- Technical
- Relative Strength Index (RSI)
- KULR 41.92
- CADL 32.96
- Support Level
- KULR $1.06
- CADL $4.25
- Resistance Level
- KULR $1.40
- CADL $5.33
- Average True Range (ATR)
- KULR 0.13
- CADL 0.47
- MACD
- KULR 0.01
- CADL -0.01
- Stochastic Oscillator
- KULR 47.06
- CADL 19.45
About KULR KULR Technology Group Inc.
KULR Technology Group Inc develops and commercializes high-performance thermal management technologies for electronics, batteries, and other components. The company is focused on targeting the following applications: electric vehicles and autonomous driving systems; artificial intelligence and Cloud computing; energy storage; and 5G communication technologies.
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.